Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway

摘要

The disclosure relates to dihydropyrazino[2,3-h]pyrazin-2(1H)-one derivative compounds of structural formula (I) shown herein or a salt, tautomer or stereoisomer thereof, wherein the variables are as defined in the specification. These compounds are suitable for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.